<DOC>
	<DOCNO>NCT00322803</DOCNO>
	<brief_summary>This study design investigate 600 mg ELB139 give orally t.i.d . patient suffer panic disorder effective reduce anxiety evoke inhalation 35 % CO2 measure visual analogue scale first intake approximately one week treatment compare placebo treatment .</brief_summary>
	<brief_title>ELB139 Given Orally Patients With Concurrent Panic Disorder , Challenged CO2 Inhalation After Single Dose One Week Treatment</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>1- ( 4-chlorophenyl ) -4-piperidin-1-yl-1,5-dihydroimidazol-2-one</mesh_term>
	<criteria>Diagnosis concurrent panic disorder At least 2 panic attack within 4 week screen visit Naïve CO2 challenge test Age 18–65 year ( inclusive ) Ability comply procedure mandate study protocol Negative pregnancy test adequate contraceptive measure History polypharmacotherapy panic disorder treatment resistance Any current psychiatric Axis I DSMIV diagnosis panic disorder , except concurrent simple phobia History abuse benzodiazepine tolerance effect benzodiazepine Any concomitant psychotropic medication Evidence impair hepatic , renal cardiac function Participation drug trial precede 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>panic disorder</keyword>
	<keyword>proof concept</keyword>
</DOC>